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Abstract: Combination therapy is necessary for most patients with hypertension, and agents 
that inhibit the renin-angiotensin-aldosterone system (RAAS) are mainstays in hypertension 
management, especially for patients at high cardiovascular and renal risk. Single blockade of 
the RAAS with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor 
blocker (ARB) confers some cardiorenal protection; however, these agents do not extinguish 
the RAAS as evidenced by a reactive increase in plasma renin activity (PRA), a cardiovascular 
risk marker, and incomplete cardiorenal protection. Dual blockade with an ACE inhibitor and 
an ARB offers no additional benefit in patients with hypertension and normal renal and left 
ventricular function. Indeed, PRA increases synergistically with dual blockade. Aliskiren, the 
first direct renin inhibitor (DRI) to become available has provided an opportunity to study the 
merit of DRI/ARB combination treatment. By blocking the first and rate-limiting step in the 
RAAS, aliskiren reduces PRA by at least 70% and buffers the compensatory increase in PRA 
observed with ACE inhibitors and ARBs. The combination of a DRI and an ARB or an ACE 
inhibitor is an effective approach for lowering blood pressure; available data indicate that such 
combinations favorably affect proteinuria, left ventricular mass index, and brain natriuretic 
peptide in patients with albuminuria,  left ventricular hypertrophy, and heart failure, respectively. 
Ongoing outcome studies will clarify the role of aliskiren and aliskiren-based combination RAAS 
blockade in patients with hypertension and those at high cardiorenal risk.
Keywords: aliskiren, valsartan, single-pill combination, hypertension, renin-angiotensin-
aldosterone system, plasma renin activity
Hypertension is a progressive condition with significant health consequences.1 Even 
slight elevations (ie, 2 mmHg) in blood pressure (BP) can substantially increase car-
diovascular and cerebrovascular risk.2,3 The ultimate goal of treating hypertension is 
to achieve and maintain a BP that will optimally reduce the risk for cardiovascular, 
cerebrovascular, and renal disease and death.4,5 However, obtaining and maintaining 
adequate control of BP can be a challenge for many high-risk patients. According 
to the US National Health and Nutrition Examination Survey (NHANES), BP is 
effectively controlled in less than 40% of patients receiving antihypertensive therapy; 
patients with diabetes or cardiovascular, cerebrovascular, or renal disease fare even 
worse, exhibiting lower BP control rates than do patients without these comorbidities.6,7 
These observations suggest that more effective treatment strategies are needed for 
physicians to help patients achieve BP goals and, ultimately, to reduce hypertension-
related disease and death.
Evidence continues to accumulate from landmark randomized trials showing the 
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patients. For example, in the ALLHAT trial, 63% of patients 
with hypertension and at least one additional cardiovascular 
risk factor required at least two antihypertensives to achieve 
a BP goal of ,140/90 mmHg after 4.9 years of follow-up.8 
In the ASCOT-BPLA trial, which included more than 19,000 
patients with hypertension and at least three additional car-
diovascular risk factors, 78% of patients required treatment 
with at least two antihypertensive agents to maintain the 
target BP (,140/90 mmHg for patients without diabetes; 
,130/80 mmHg for patients with diabetes).9 In AASK, 
an average of three agents were needed to achieve a mean 
arterial pressure goal of #92 mmHg.10 Because combina-
tion treatment is eventually necessary, published guidelines 
recommend it as initial treatment for most patients, especially 
those with initial high BP and those with cardiovascular or 
renal risk.4,5,11 This approach also allows patients to achieve 
the BP goal more quickly. In the ACCOMPLISH trial, 
in which 11,506 patients with high risk for hypertension 
were randomly assigned to receive combination therapy, 
73% of patients were able to achieve BP control within 
6 months.12,13
It is expected that prompt control of BP will discourage 
therapeutic inertia and might improve outcomes in patients 
with hypertension; however, few studies have been aimed at 
evaluating the relationship of attainment of early BP control 
with cardiovascular outcomes. The VALUE trial enrolled 
patients with hypertension and a history of cardiovascu-
lar disease, diabetes, or stroke. Attainment of BP control 
(systolic BP #140 mmHg) within 6 months was associated 
with a significant reduction in the risk for cardiovascular 
events and death, regardless of the type of drug used.14 Fur-
thermore, in the ASCOT trial, relative to those receiving an 
atenolol-based combination therapy regimen, hypertensive 
patients receiving an amlodipine-based regimen exhibited a 
significant reduction in the total number of coronary events 
associated with superior BP control, which was evident by 
1 year of treatment.9 Finally, the Syst-EUR trial found that, 
compared with delayed treatment and control, early treatment 
and control of BP in hypertensive adults 60 years or older 
resulted in a significant reduction in the frequency of, and 
risk (adjusted relative hazard) for, stroke and major cardio-
vascular events.15 In this study, delayed onset of antihyper-
tensive treatment also showed benefit in clinical outcomes by 
reduction of systolic BP in patients, albeit to a lesser extent 
than in the early-treatment group. The soon-to-be-released 
Joint Commission (JNC-8) recommendations are expected 
to further highlight the importance of the use of combina-
tion therapy early in the hypertension treatment algorithm. 
Contemporary evidence from the studies noted herein will be 
incorporated into the updated guidelines as further evidence 
of the value of logical combination therapy for securing more 
effective and earlier BP control and improved outcomes. 
Combinations that include a renin-angiotensin-aldosterone 
system (RAAS) antagonist, such as an angiotensin-converting 
enzyme (ACE) inhibitor or an angiotensin receptor blocker 
(ARB), plus a calcium channel blocker or thiazide diuretic are 
the most effective, well-tolerated, and proven strategies.11
The role of the RAAS in 
hypertension management
The role of the RAAS in cardiovascular and renal homeosta-
sis is well established, as is the role of an up-regulated RAAS 
in cardiovascular disease such as hypertension and ischemic 
heart disease.16 Angiotensin II, the major effector peptide 
of the RAAS, contributes to the progression of target organ 
damage via a number of hemodynamic and cellular actions 
(Figure 1). By promoting vasoconstriction and aldosterone 
release and by increasing oxidative stress, as well as aug-
menting the production of cytokines, adhesion molecules, 
and growth factor in these target tissues, angiotensin II plays 
a pivotal role in cardiovascular and renal disease. Some of 
the other pathologic effects of angiotensin II include cardiac 
and vascular remodeling, inflammation, thrombosis, and even 
plaque rupture, the ultimate and lethal step in atherosclero-
sis.17 With regard to renal disease, angiotensin II is partially 
responsible for promoting albuminuria and accelerating the 
decrease in the glomerular filtration rate associated with 
diabetic nephropathy, the leading cause of end-stage renal 
disease in the modern world.18 Inhibitors of RAAS, such as 
ARBs, and, more recently, the direct renin inhibitor aliskiren, 
alone and in combination with an ARB, has been shown to 
slow the decrease in glomerular filtration rate and diminish 
albuminuria in patients with diabetic nephropathy.19,20 In 
addition to angiotensin II, other RAAS components have 
been cited as biomarkers of cardiovascular risk. Elevated 
levels of plasma renin activity (PRA) have been shown 
to be independently associated with an increased risk for 
myocardial infarction (MI) in patients with hypertension.21 
More recently, in an analysis of 2913 patients with stable 
vascular disease or diabetes who were enrolled in the HOPE 
study, an elevated PRA was found to be associated with a 
49% increase in the risk for major   cardiovascular events.22 
In 1172 patients with severe coronary artery disease with 
no history of cardiac events, elevated PRA independently 
predicted a 40% increased risk for death and a twofold 
increased risk for hospitalization for congestive heart failure Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Figure 1 The renin-angiotensin-aldosterone system. 
Abbreviations: DRi, direct renin inhibitor; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AT, angiotensin ii receptor, type1/2; NO, nitric oxide.
(CHF) during long-term (.5 years)   follow-up.23 Evidence 
is also accumulating that the overproduction of aldosterone 
increases cardiovascular risk independent of its effects on 
BP, and, similar to angiotensin II, promotes inflammation, 
oxidative stress, and fibrosis.24
Although pharmacologic manipulation of the RAAS 
with ACE inhibitors and ARBs improves outcomes in hyper-
tension and cardiovascular and renal disease, it provides 
only partial protection from disease progression (Table 1). 
This might be explained by the contributions of other 
mechanisms to disease or progression or by the inadequacy 
of ACE   inhibitors and ARBs. Possible mechanisms for the 
inadequacies include interruption of negative feedback 
and a compensatory increase in renin and angiotensin   
I levels, which can overcome ACE inhibition or result in   
the production of angiotensin II by non-ACE pathways 
(ie, ACE escape).25 Further, the inability of ARBs to occupy 
all angiotensin II type (AT)1 receptors at any given time26 
and aldosterone breakthrough27,28 during ACE inhibition or 
ARB use are additional possible mechanisms for this lack 
of complete protection by ACE inhibition and angiotensin 
receptor blockade. For these reasons, inhibition of renin (the 
first and rate-limiting step in the RAAS; Figure 1) has long 
been a pharmacologic target for RAAS blockade; however, 
only recently has aliskiren emerged as the first direct renin 
inhibitor (DRI) available for clinical use.29 By inhibiting 
the conversion of angiotensinogen to angiotensin I and by 
decreasing PRA, aliskiren may provide a more complete Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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blockade of the RAAS and offers a new opportunity to 
explore multistep RAAS blockade.
The remainder of this article is directed at evaluating the 
experience accumulated with combination DRI/ACE or ARB, 
discussing the differences between dual RAAS blockade 
with ACE inhibitors/ARBs and DRI plus an ACE inhibitor 
or an ARB, and reviewing the role of combination aliskiren/
valsartan in the treatment of hypertension.
Dual RAAS blockade
ACE inhibitor plus ARB
The success of single RAAS blockade with an ACE inhibitor 
or an ARB led researchers to theorize that dual RAAS block-
ade might confer an even greater benefit on BP lowering 
and cardiorenal outcomes. Unfortunately, this has not been 
consistently demonstrated. Combining an ACE inhibitor 
and an ARB produces only small, incremental reductions 
in BP. In a meta-analysis of randomized controlled trials 
in which ACE inhibitors and ARBs were administered in 
combination for the treatment of hypertension (defined as 
a sitting systolic BP [SBP] $140 mmHg and/or diastolic 
BP [DBP] $90 mmHg; mean ambulatory SBP or DBP 
of $130 mmHg or 85 mmHg, respectively; or use of anti-
hypertensive agents), ambulatory SBP/DBP was reduced 
overall by 4.7/3.0 mmHg, compared with ACE inhibitor 
monotherapy, and by 3.8/2.9 mmHg, compared with ARB 
monotherapy.30 Reductions in sitting SBP/DBP relative to 
ACE inhibitor or ARB monotherapy were 3.8/2.7 mmHg 
and 3.7/2.3 mmHg, respectively. Surrogate end point and 
outcome studies have not consistently shown clinical ben-
efits of ACE inhibitor/ARB combination therapy compared 
with respective monotherapies (Table 2). Most recently, 
  ONTARGET, the largest of these studies, determined 
that combining the ACE inhibitor ramipril with the ARB 
telmisartan did not provide high-risk patients who have 
hypertension with any additional cardiovascular protection 
than an ACE inhibitor or an ARB alone.31,32 These results 
were unexpected and suggest that administration of an 
ACE inhibitor plus an ARB may not be optimal for block-
ing RAAS in patients with hypertension but without left 
ventricular dysfunction or kidney disease. Consequently, 
this approach should not be routinely prescribed for such 
patients.
It is not clear why combination RAAS blockade was 
unsuccessful in ONTARGET; however, several mechanisms 
are worthy of consideration. Perhaps single-step RAAS 
blockade sufficiently diminishes the deleterious effects of 
RAAS so that further blockade does not provide a measurable 
clinical benefit in this population. This does not seem likely 
because ACE inhibitors and ARBs do not fully extinguish 
overactive RAAS activity in high-risk patients and because 
higher doses of ACE inhibitors and ARBs have been shown 
to improve outcomes.33,34 It could also be that the population 
enrolled in ONTARGET was well treated at baseline, result-
ing in a low event rate, which would require longer follow-up 
or a higher risk population for the benefit to be detected. 
The findings might also be inherent to the combination of 
an ACE inhibitor and an ARB. The combination did not 
markedly lower BP, compared with the single RAAS agent 
regimens. Additionally, combination ACE inhibitor/ARB 
treatment potentiates an exponential increase in PRA, which 
could further drive ACE and aldosterone escape pathways 
(Figure 1).
Although the combination of an ACE inhibitor and an 
ARB interrupts two important steps in the RAAS pathway, 
it does not interfere with the rate-limiting step in the path-
way: the conversion of angiotensinogen to angiotensin I 
by renin. Several studies have underscored the importance 
of this step, measured as PRA, in predicting the risk for 
cardiovascular events. In the SAVE trial, in patients with 
acute MI, two neurohormones (PRA and atrial natriuretic 
peptide) were independently predictive of future cardiovas-
cular disease (assessed by multivariate analysis).35 Elevated 
PRA at the time of hospital discharge for acute MI was 
associated with a 60% increased risk for total cardiovas-
cular disease and a 100% increased risk for severe heart 
failure. In the Val-HeFT study, higher baseline PRA was 
associated with increased rates of morbidity and mortality 
in patients with stable moderate to severe heart failure.36 
Whether the introduction of an RAAS antagonist, such as 
aliskiren, that reduces PRA levels is capable of offering 
greater cardioprotection is a question that has only recently 
been entertained.
Aliskiren plus ACE inhibitor or ARB
Researchers have shown that additional reductions in BP 
can be achieved when aliskiren is combined with an ACE 
inhibitor or an ARB.37,38 In pilot studies, the addition of 
aliskiren 150 mg once daily to ramipril 5 mg once daily for 
3 weeks lowered ambulatory daytime and nighttime SBP an 
additional 7 to 8 mmHg; when added to once-daily irbesar-
tan 150 mg, aliskiren reduced daytime SBP an additional 
1.9 mmHg and nighttime SBP an additional 4.2 mmHg.37 
In another study, oncedaily aliskiren 150 mg/ramipril once-
daily 10 mg for 8 weeks reduced mean sitting SBP/DBP 
by an additional 4.6/2.1 mmHg,   compared with ramipril Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 2 Outcome studies that included combination treatment with ACE inhibitors and ARBs
Cardiovascular disease
Study Patients Daily treatment 
regimen
Mean follow- 
up
Main outcome Main findings with combination 
therapy
VALiANT70 4909 
4909 
4885 
Acute Mi patients  
with HF/LVD 
Valsartan 
Captopril 
Both
24.7 months Death Combination did not improve survival 
relative to either monotherapy (19%–
20% in each group died) or other key 
secondary outcomes despite additional 
BP lowering. The combination group 
experienced more AEs than either 
monotherapy group
CHARM- 
added71
2548 patients with  
HF and LVD receiving 
ACE inhibitor
Candesartan or 
placebo
41 months CV death or HF 
hospitalization
Outcomes experienced by 42% of 
patients in placebo group and 38% 
in candesartan group (P = 0.011). 
Combination produced larger BP 
reductions but caused more patients 
to discontinue treatment for AEs (24% 
versus 18%; P = 0.0003)
Val-HeFT66 5010 patients  
with HF 
Valsartan 160 mg 
vs placebo
23 months Death and death 
plus cardiac arrest,  
HF hospitalization,  
or need for 
vasodilators
Among the 366 patients who were 
receiving an ACE inhibitor plus a 
β-blocker, valsartan adversely affected 
total risk of death; among the 366 patients 
not receiving an ACE inhibitor, valsartan 
↓ risk for death 33% and composite 
end point 44% (versus 0% and ↓13% for 
combined valsartan/ACE inhibitor)
ONTARGET31 8576 
8542 
8502 
Patients with vascular 
disease or high-risk 
diabetes without HF
Ramipril 10 mg 
Telmisartan 80 mg 
Both
56 months Composite of CV 
death, Mi, stroke, 
or HF 
hospitalization 
Primary outcome occurred to a similar 
degree in each group (16.3%–16.7% 
patients)
Compared with ramipril, greater rates of 
hypotensive symptoms with combination 
(4.8%) (1.7%; P , 0.001) and renal 
dysfunction (13.5% versus 10.2%; P , 0.001)
Renal outcomes
CALM72 199 patients with 
hypertension, type 2 
diabetes, and MAU 
Candesartan or 
lisinopril, followed 
by candesartan, 
lisinopril, or the 
combination
12 weeks Change in 
UACR and BP
UACR reduced 50% with combination, 
24% with candesartan, and 39% with 
lisinopril (P = 0.04 for combination vs 
candesartan and .0.20 versus lisinopril BP 
reduced 25.3/16.3, 14.1/10.4, and 16.7/ 
10.7 mmHg with combination, candesartan 
and lisinopril (P # 0.005 for either 
monotherapy versus combination) 
iMPROVE73 405 hypertensive, 
high risk CV 
patients with MAU
Ramipril plus 
irbesartan 
Ramipril plus 
placebo
20 weeks Change in UAER UAER reduced 46% with combination 
versus 42% with ramipril/placebo;  
P = 0.540
AEs similar between groups
ONTARGET32 8576 
8542 
8502
Ramipril 10 mg 
Telmisartan 80 mg 
Both
56 months Composite renal 
outcome of 
doubling of SCr, 
ESRD, or death 
Main outcome occurred most frequently 
with combination (14.5%; P = 0.037) 
versus 13.4% with telmisartan and 13.5% 
with ramipril
eGFR decrease (mL/min/1.73m2): 
ramipril, -2.82; telmisartan, -4.12; 
combination, -6.11; (P , 0.001 
comparisons with ramipril)
worse outcomes despite reduced 
proteinuria with combination therapy
Combination had no clear benefit in 
overt diabetic nephropathy
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; Mi, myocardial infarction; HF, heart failure; LVD, left ventricular dysfunction; BP, 
blood pressure; AE, adverse event; MAU, microalbuminuria; UACR, urinary albumin/creatinine ratio; CV, cardiovascular; UAER, urinary albumin excretion rate; AEs, adverse 
events; SCr, serum creatinine; ESRD, end stage renal disease; eGFR, estimated glomerular filtration rate.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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monotherapy in patients with   diabetes (P # 0.01).38 In 
healthy volunteers, therapeutic doses of aliskiren produced 
long-lasting increases in renal plasma flow, the magnitude of 
which far exceeded that of either the use of an ACE inhibi-
tor or an ARB. Accompanying the increased renal plasma 
flow was a significant increase in natriuresis, indicating 
more effective RAAS blockade.39 In addition, results of two 
recent studies show the enhanced renoprotective effects of 
aliskiren when combined with maximal ARB treatment in 
type 2 diabetes, independent of any additional BP-lowering 
effects.20,40 When aliskiren (150 mg daily for 3 months, 
then 300 mg daily for 3 months) was added to once-daily 
losartan 100 mg in 599 patients in the AVOID study, the 
mean urinary/albumin creatinine ratio was reduced by an 
additional 20% relative to losartan-only (placebo group) 
treatment (P , 0.001), with only a small difference in BP-
lowering (an additional 2/1 mmHg lower).20 Adverse event 
profiles were similar between aliskiren/losartan and losartan 
alone. In the second study, placebo, aliskiren 300 mg once 
daily, irbesartan 300 mg once daily, or the combination of 
aliskiren/irbesartan were directly compared for 2-month 
treatment periods in a 4 × 4 crossover design in 26 patients.40 
Compared with the rates for placebo, albuminuria and 
albumin fractional clearance rates were reduced 58% and 
46% with irbesartan, 48% and 56% with aliskiren, and 71% 
and 67% with the combination (P # 0.028 and P = 0.001 
versus either monotherapy), respectively.
The effects of aliskiren on surrogate markers of cardio-
vascular disease when combined with ACE inhibitors or 
ARBs have been examined in at least two studies.41,42 The 
ALOFT study enrolled 302 patients with heart failure and 
hypertension who were already receiving stable doses of ACE 
inhibitors or ARBs and β-blockers. Patients were treated with 
aliskiren 150 mg or placebo daily for 3 months.41 The primary 
efficacy end point in the study was the between-treatment 
levels of plasma N-terminal-pro-brain natriuretic peptide 
(NT-proBNP), a neurohormone biomarker that forecasts an 
increased risk for events in heart failure (HF) patients.36 At 
the end of the study period, mean plasma NT-proBNP levels 
were elevated by 762 pg/mL with placebo but decreased sig-
nificantly by 244 pg/mL with aliskiren (P = 0.0106). Urinary 
aldosterone (aldosterone is a downstream component of the 
RAAS cascade and urinary excretion is therefore a measure of 
the neurohormonal effect of aliskiren) decreased 9.24 nmol/d 
with aliskiren and 6.96 nmol/d with placebo (P = 0.0150), with 
no difference in plasma aldosterone or BP between groups. 
In the second study, the ALLAY trial,42 465 hypertensive 
patients with left ventricular hypertrophy (LVH; left ven-
tricular wall thickness $13 mm) and a body mass index 
.25 kg/m2 were recruited. Patients were randomly assigned 
to receive 9 months of treatment with once-daily aliskiren 
300 mg, losartan 100 mg, or a combination of both doses. If 
a study patient was receiving an ACE inhibitor or an ARB, 
they underwent a 3-month washout period prior to treatment. 
Left ventricular mass index was significantly reduced from 
baseline with losartan (4.8 g/m2; 4.7%), aliskiren (4.9 g/m2; 
5.4%), and the combination (5.8 g/m2; 6.4%; P , 0.0001 for 
each treatment group); differences between the combination 
and losartan monotherapy were not significant (P = 0.52). 
Blood pressure reductions were similar between groups. None 
of these studies showed any safety concerns with the combina-
tion of aliskiren plus an ACE inhibitor or an ARB, compared 
with monotherapy. Specifically, there were no differences in 
adverse events, including renal dysfunction, hyperkalemia, 
and discontinuation due to adverse events, including patients 
at risk for renal events (ie, with renal impairment and diabe-
tes). Frequency of cough was less with the combination of 
aliskiren/ramipril (1.8%) than with ramipril monotherapy 
(4.7%) in the 8-week hypertension study,38 though this dif-
ference was not significant (P = 0.08).
Uniqueness of DRi-based combinations
When an ACE inhibitor and an ARB are combined, each 
signals a large reactive increase in PRA. Conversely, a 
DRI-based combination therapy buffers the ACE inhibitor 
or ARB-induced increases in PRA such that the net effect 
on PRA is an approximate 50% reduction43   ( Figures 2 
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and 3).37,43–45 Reductions in PRA with aliskiren are sus-
tained over 26 weeks of treatment and persist 4 weeks 
after discontinuation.45 Suppression of PRA with aliskiren 
monotherapy and diminution of ACE inhibitor-induced 
and ARB-induced increases in PRA distinguishes DRI’s 
mechanism of action from other RAAS inhibitors.Team-
ing aliskiren with an ARB functionally blocks the RAAS 
at the first and rate-limiting step and final receptor; this 
complementary mechanism provides significant reductions 
in PRA, angiotensin I, angiotensin II, and aldosterone.46 
Theoretically, any angiotensin I that is formed despite 
aliskiren treatment will be converted to angiotensin II 
and then bind at the unoccupied AT2 receptor, eliciting 
favorable effects.
Combining a DRI with an ACE inhibitor blocks sequen-
tial steps in the RAAS cascade. Angiotensin I that is formed 
despite aliskiren treatment will be inhibited from conversion 
to angiotensin II by the ACE inhibitor. Angiotensin II that 
might be formed despite this dual blockade would bind and 
activate either AT receptor. Bradykinin potentiation will 
occur because of ACE inhibition. With either DRI combina-
tion, PRA is suppressed and formation of angiotensin I is 
greatly reduced, thus providing less substrate to drive escape 
pathways.
Aliskiren plus valsartan
The combination of aliskiren and the ARB valsartan was 
recently approved as a single-pill combination (SPC). 
Results of several studies support the BP-lowering effec-
tiveness of combination therapy with these agents. In 
a study involving 1797 patients with mean sitting DBP 
between 95 and 109 mmHg and 8-hour daytime ambula-
tory DBP $90 mmHg, sitting SBP/DBP was reduced 
by 17.2/12.2 mmHg with once-daily aliskiren 300 mg/
valsartan 320 mg, by 13.0/9.0 mmHg with aliskiren 
300 mg, by 12.8/9.7 mmHg with valsartan 320 mg, and 
by 4.6/4.1 mmHg with placebo after 8 weeks of treat-
ment (P , 0.0001 for combination versus monotherapy 
or placebo).47 In a subset of 581 patients with stage 
2 hypertension (SBP $160 mmHg) from this study, 
BP reductions were even more pronounced, in favor 
of the combination treatment, with mean reductions in   
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Table 3 Laboratory abnormalities occurring during treatment with placebo, aliskiren 300 mg daily, valsartan 320 mg daily, or the 
combination of aliskiren 300 mg/valsartan 320 mg: results from an 8-week randomized, double-bind, placebo-controlled study and a 
6-month, open-label study in patients with hypertension47,49
Laboratory abnormality Number (%) of patients
8-week study47 6-month, open-label study49
Placebo 
n = 458
Aliskiren 
n = 437
Valsartan 
n = 455
Aliskiren/valsartan 
n = 446
Aliskiren/valsartan 
n = 396
Aliskiren/valsartan/HCTZ 
n = 588
Potassium
,3.5 mmol/L 17 (4) 11 (3) 20 (4) 12 (3) 6 (1.5) 13 (6.8)
.5.5 mmol/L 12 (3) 7 (2) 7 (2) 18 (4) 10 (2.5) 2 (1.0)
$6.5 mmol/L 6 (1) 4 (1) 5 (1) 2 (0.5) 1 (0.3) 0
Creatinine .176.8 μmol/L 0 1 (0.2) 2 (0.4) 4 (0.9) 1 (0.3) 1 (0.5)
Blood urea nitrogen  
.14.3 mmol/L
0 1 (0.2) 1 (0.2) 0 1 (0.3) 2 (1.0)
Abbreviation: HCTZ, hydrochlorothiazide (up to 25 mg daily).
SBP/DBP of 22.5/11.4 mmHg with the combination   
compared with 17.3/8.9 mmHg with aliskiren, 15.3/8.3 mmHg 
with valsartan, and 7.9/3.7 mmHg with placebo (P # 0.05 
for comparisons with monotherapy or placebo).48 In a 
6-month open-label study of 601 patients with hyperten-
sion (defined as having a mean sitting DBP between 90 and 
109 mmHg), BP reductions were sustained with continued 
treatment. Mean SBP/DBP was reduced from baseline by 
22.3/14.4 mmHg with once-daily aliskiren 300 mg/valsartan   
320 mg.49
The combination of maximal dose (300 mg/320 mg) 
aliskiren/valsartan exhibited a safety and tolerability pro-
file similar to that of monotherapy with either agent. In 
the 8-week study involving 1797 hypertensive patients,47 
adverse events and laboratory abnormalities occurred to 
a similar degree among all treatment groups. Headache 
was the main adverse event reported with the combina-
tion (reported in 4% of patients), which was less than 
with valsartan (5%) and placebo (9%). The proportion 
of patients experiencing increases in clinically relevant 
laboratory values is shown in Table 3. Overall, few 
patients experienced increases in serum potassium, crea-
tinine, and blood urea nitrogen levels during treatment. 
In addition, in patients with elevated serum potassium 
levels .5.5 mmol/L at any time after baseline, serum 
potassium values returned to normal in 13 of 18 patients 
(72%), without necessitating treatment discontinuation. 
During the 6-month open-label study,49 postbaseline serum 
potassium values .5.5 mmol/L were infrequent and tended 
to be transient. Only two patients in this 6-month study 
(0.3%) who received aliskiren/valsartan plus hydrochlo-
rothiazide (HCTZ) were discontinued from treatment as 
a result of hyperkalemia.
Role of aliskiren/valsartan  
in the hypertension therapeutic 
armamentarium
Based on the established efficacy and safety profile of 
aliskiren/valsartan, this SPC is attractive for first-line use in 
the treatment of hypertension for those patients who have 
diabetes or who are at high risk for cardiovascular disease 
and are not likely to achieve BP goals with monotherapy, 
or as a second-line treatment for patients who have not 
achieved BP control with either an ACE inhibitor or ARB 
alone. In an 8-week comparative trial,50 once-daily aliskiren 
300 mg/valsartan 320 mg provided comparable reductions 
to once-daily valsartan 160 mg/HCTZ 12.5 mg, another SPC 
that can be used for initial and second-line treatment for 
hypertension. SPCs provide an attractive treatment choice 
because they can improve patient adherence to hypertension 
treatment, compared with administration of two separate 
agents.51,52
The effects of aliskiren combined with another RAAS 
agent on various surrogate end points in the AVOID, 
ALOFT, and ALLAY studies (proteinuria, NT–proBNP, 
LVH) suggest that aliskiren-based combinations may 
confer incremental vasculoprotective effects that are not 
accounted for by BP reductions alone and, therefore, may 
be particularly appealing for treatment of hypertension in 
patients with diabetes, kidney disease, or the metabolic 
syndrome.26,41,42,53 More long-term data are needed to con-
firm its efficacy and safety in these patient populations. 
Moreover, the importance of neurohormonal activation in 
cardiovascular disease, and more specifically, the prog-
nostic role of increased PRA with cardiovascular disease, 
signal a potential role for aliskiren in this regard and 
support the evaluation of aliskiren/ARB combinations in Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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outcomes studies. In addition, aliskiren either by itself or 
in combination with the ARB valsartan has been shown to 
have a potential benefit on reducing urinary aldosterone 
levels.47 This mineralocorticoid hormone, aldosterone, is 
associated with the development of not only hyperten-
sion, but of cardiovascular and renal diseases as well.54,55 
In addition to having a hemodynamic effect, aldosterone 
is associated with inflammation, platelet aggregation, 
hypertrophy, and fibrosis.56,57 Drugs such as eplerenone 
(a spironolactone derivative) that attenuate the activity 
of aldosterone have been shown to reduce the morbidity 
and mortality associated with heart failure and post-
MI.54 Therefore, an incremental reduction in aldosterone, 
by combining a DRI with an ACE-inhibitor or ARB, is 
expected to translate into organ protection and might 
explain the benefits observed to date in heart failure, 
diabetes mellitus associated nephropathy as well as 
LVH.22,47,58 The ASPIRE HIGHER program was undertaken 
to evaluate potential cardiorenal effects of aliskiren over 
a spectrum of conditions in 14 different studies involving 
more than 35,000 patients.59 To date, this is the largest and 
most comprehensive cardiorenal program undertaken to 
evaluate a particular pharmacologic intervention. Three 
of the studies evaluating surrogate end points have been 
discussed herein (AVOID, ALLAY, and ALOFT) and favor-
able effects of adding aliskiren to standard treatment have 
been found. The ASPIRE HIGHER program also includes 
four morbidity and mortality trials (Table 4), which were 
designed with the aim of improving the standard of care by 
adding a DRI to current best practice and also to elucidate 
the role of DRI therapy in situations in which there is no 
established effective standard of care. Results from the first 
of these trials (ALTITUDE) are expected in 2012.58
Conclusion
ACE inhibitors and ARBs have been valuable in improving 
outcomes in cardiovascular and renal diseases; however, 
there remains significant residual risk of cardiovascular 
events even when these agents are used, which could be 
attributable to incomplete blockade of the RAAS. In fact, 
ACE inhibitors and ARBs silence negative feedback control 
of RAAS and accelerate the production of angiotensin I. For 
this reason, direct renin inhibition has long been considered 
a possible therapeutic mechanism for hypertension and 
cardiovascular disease. The availability of aliskiren for the 
treatment of hypertension signals the beginning of a new 
era in RAAS blockade. Aliskiren’s unique mechanism of 
action and ability to buffer PRA justifies its availability as an 
SPC with valsartan. Initial studies in patients with diabetic 
nephro  pathy, LVH, and HF have shown promising effects 
on surrogate markers and long-term outcome studies are 
under way; results are eagerly awaited. In the meantime, the 
combination of aliskiren plus valsartan affords clinicians 
an SPC agent with demonstrated superior RAAS protection 
and safe and effective BP lowering, making the combination 
an important addition to the antihypertensive repertoire.
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Table 4 Cardiovascular morbidity and mortality outcome studies with aliskiren in the ASPiRE HiGHER program
Study  Patients n Intervention Primary outcome Planned 
follow-up
ALTiTUDE Type 2 diabetes and at high 
risk for fatal and nonfatal 
cardiorenal events 
8600 Aliskiren 300 mg or placebo 
on top of conventional 
treatment (ACE inhibitor or 
ARB plus others)
Time to first event of CV death,  
resuscitated sudden death, Mi, stroke,  
unplanned HF hospitalization, 
ESRD, renal death, doubling of SCr 
sustained for $1 month
4 years
ATMOSPHERE Chronic HF  7041 Aliskiren 300 mg, enalapril  
10 mg, or a combination
Time to first event of CV death or HF 
hospitalization
4 years
ASTRONAUT Hospitalized for worsening HF  1782 Aliskiren 300 mg or placebo 
on top of standard therapy
Time to first occurrence of CV death 
or HF rehospitalization within 6 months
6 months
APOLLO  Elderly patients with normal  
to high BP and high CV risk
Study in development
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CV, cardiovascular; Mi, myocardial infarction; HF, heart failure; ESRD, end stage 
renal disease; SCr, serum creatinine; BP, blood pressure.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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